Myo-inositol reduces β-catenin activation in colitis

World J Gastroenterol. 2017 Jul 28;23(28):5115-5126. doi: 10.3748/wjg.v23.i28.5115.


Aim: To assess dietary myo-inositol in reducing stem cell activation in colitis, and validate pβ-cateninS552 as a biomarker of recurrent dysplasia.

Methods: We examined the effects of dietary myo-inositol treatment on inflammation, pβ-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran sodium sulfate-treated colitic mice. Additionally, we assessed nuclear pβ-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia.

Results: In mice, pβ-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, pβ-cateninS552 staining discriminated ulcerative colitis patients with a history of LGD from those with benign disease.

Conclusion: Enumerating crypts with increased numbers of pβ-cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

Keywords: Biomarker; Chemoprevention; Colitis-associated cancer; Dysplasia; Stem cell.

Publication types

  • Clinical Trial

MeSH terms

  • Animals
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / metabolism*
  • Biopsy
  • Cell Nucleus / metabolism
  • Cell Proliferation
  • Colitis, Ulcerative / chemically induced
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / pathology
  • Colon / cytology
  • Colon / drug effects
  • Colon / pathology
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / prevention & control
  • Dextran Sulfate / toxicity
  • Disease Models, Animal
  • Humans
  • Immunohistochemistry
  • Inositol / pharmacology*
  • Inositol / therapeutic use
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism
  • Mice
  • Mice, Knockout
  • Phosphorylation
  • Pilot Projects
  • Placebos
  • Signal Transduction
  • Stem Cells / drug effects
  • beta Catenin / analysis
  • beta Catenin / metabolism*


  • Biomarkers, Tumor
  • CTNNB1 protein, human
  • CTNNB1 protein, mouse
  • IL10 protein, mouse
  • Placebos
  • beta Catenin
  • Interleukin-10
  • Inositol
  • Dextran Sulfate